Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting
GALAXY-1 interim results
“A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)”
Abstract #: CRA8007
Date and time:
Location:
Oral Abstract Session – Lung Cancer. E Hall D2
Presenter: Suresh S.
Ramalingam, M.D.,
The interim overall survival analysis of the adenocarcinoma patient
population of GALAXY-1 planned for six months from the
GALAXY-2 and ENCHANT-1 trial designs
“GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma”
Abstract #: TPS8126
Date and time:
Location:
General Poster Session – Lung Cancer. S Hall A2
Presenter: Dean A.
Fennell, M.D., Ph.D., University Hospitals of
“The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple negative breast cancer (TBNC)”
Abstract #: TPS1136
Date and time:
Location:
General Poster Session – Breast Cancer. S Hall A2
Presenter:
Investigator-sponsored studies
“A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers”
Abstract #: 4090
Date and time:
Location:
General Poster Session – Gastrointestinal (noncolorectal) Cancer. S Hall
A2
Presenter:
“A phase II clinical trial of ganetespib (STA-9090), a heat shock
protein 90 (Hsp90) inhibitor, in heavily pretreated patients with
metastatic castration-resistant prostate cancer (mCRPC) post
docetaxel-based chemotherapy: Results of a
Abstract #: 5085
Date and time:
Location:
General Poster Session – Genitourinary Cancer. S Hall A2
Presenter:
“Heat shock protein 90 (HSP90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): an in vitro analysis with a focus on p16 status”
Abstract #: 2552
Time:
Location:
General Poster Session – Developmental Therapeutics. S Hall A2
Presenter:
Abstract content
Except for the GALAXY-1 abstract (CRA8007), which is expected to remain
under embargo until
About Ganetespib
Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in “oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in over 20 clinical trials including trials in lung, breast, colorectal, and hematologic malignancies. Information on these trials can be found at www.clinicaltrials.gov.
About the GALAXY Program
The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program consists of two randomized trials comparing the combination of ganetespib and docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More information about the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126 and NCT01798485).
About
Safe Harbor Statement
This media release may contain forward-looking statements about
Source:
Investor Relations Contact:
Synta Pharmaceuticals Corp.
George
Farmer, 781-541-7213
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media
Contact:
Q Communications
Eliza Schleifstein, 973-361-1546
[email protected]